| Popis: |
Introduction: Omalizumab is an anti-IgE monoclonal antibody used for treatment of uncontrolled severe asthma and it has shown efficacy during clinical development; however, real life data is lacking for an accurate assessment. Objective: Efficacy assessment of Omalizumab treatment. Methods: Retrospective observational study of patients with severe asthma under add-on treatment with Omalizumab, observed in a Pulmonology department of a tertiary hospital. The following criteria were analyzed: number of exacerbations, forced expiratory volume in one second, symptoms (Asthma Control Test) and inhaled treatment in baseline and in 1 year after treatment initiation (equivalent daily dose of budesonide). Seven patients were excluded from the study since they did not complete 1 year of treatment. Results: 21 patients were included in the study (mean age 48±10 years-old; 76.2% women). Eight patients (38.1%) were previously treated with specific immunotherapy. IgE total mean at baseline was 327,2±324,9 UI/ml. Conclusions: After 12 months of Omalizumab, patients had symptomatic improvement (reduction of total exacerbations and higher scores in ACT), improvement in lung function (FEV1), reductions of daily mean dose of inhaled corticosteroids and suspension of oral corticosteroids, proving its therapeutic efficacy. |
